Shots:
- Daiichi has reported first pts dosing in its P-III (DESTINY-Gastric05) trial assessing Enhertu regimen in 1L, inoperable, locally advanced or metastatic HER2+ (IHC 3+ or IHC 2+/ISH+) G/GEJ cancer pts, with PD-L1 CPS ≥1
- Trial will assess efficacy & safety of Enhertu (5.4mg/kg) + Keytruda + fluoropyrimidine-based CT vs trastuzumab + Keytruda + Pt-based CT in above pts (n=576), whereas an exploratory cohort of 150 pts with PD-L1 CPS <1 will be randomized to Enhertu + fluoropyrimidine CT or trastuzumab + Pt-based CT
- Trial will evaluate PFS per BICR (1EP) along with 2EPs incl. PFS assessed by investigator, ORR, DoR & safety in pts across Asia, Europe, North & South America
Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
